Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECT CLL: Pneumococcal Vaccine Series in CLL
NCT05183854Phase 2Recruiting
- Sponsor
- University of Utah
- Start
- Jan 2022
- Primary completion
- Mar 2027
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of Prevnar 20 and 23-valent pneumococcal polysaccharide vaccine in pneumococcal disease (2 arms), sponsored by University of Utah. Primary endpoint: Proportion of patients who achieve the protocol defined change in antibody titers at 90 days. Started Jan 2022; status: recruiting.
02
Drugs
Prevnar 2023-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT05183854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05183854.